Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine

Background: The aim of the present study was to assess the migraine outcome, in particular migraine disability, in chronic (CM) and high frequency episodic migraine (HFEM) patients in treatment with galcanezumab. Methods: The present study was conducted at the Headache Centre of Spedali Civili of Br...

Full description

Bibliographic Details
Main Authors:	Francesca Schiano di Cola, Marco Bolchini, Salvatore Caratozzolo, Giulia Ceccardi, Matteo Cortinovis, Paolo Liberini, Renata Rao, Alessandro Padovani
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Neurology International
Subjects:	migraine CGRP disability burden MIDAS HIT-6
Online Access:	https://www.mdpi.com/2035-8377/15/1/17

Similar Items

Photophobia and migraine outcome during treatment with galcanezumab
by: Francesca Schiano di Cola, et al.
Published: (2023-01-01)

Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine
by: Giulia Ceccardi, et al.
Published: (2023-11-01)

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
by: Peter McAllister, et al.
Published: (2022-08-01)

Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
by: Zaira Maraia, et al.
Published: (2021-09-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-01-01)

MIDAS (Migraine Disability Assessment): a valuable tool for work-site identification of migraine in workers in Brazil
by: Yara Dadalti Fragoso

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-10-01)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
by: Angelo Camporeale, et al.
Published: (2018-11-01)

Effect of pranayama as adjuvant to medical treatment on severity, frequency, and duration of headache in migraine patients: An open-label randomized controlled trial
by: Anjana Kaushal, et al.
Published: (2023-01-01)

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial
by: Todd J. Schwedt, et al.
Published: (2023-11-01)

Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials
by: Jakub Jedynak, et al.
Published: (2021-05-01)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
by: Cohen F, et al.
Published: (2022-04-01)

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
by: Dulanji K. Kuruppu, et al.
Published: (2021-04-01)

CGRP-targeted medication in chronic migraine - systematic review
by: Renato Oliveira, et al.
Published: (2024-04-01)

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
by: Marina de Tommaso, et al.
Published: (2022-04-01)

Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
by: Marcello Silvestro, et al.
Published: (2022-06-01)

Interictal osmophobia is associated with longer migraine disease duration
by: Gudrun Gossrau, et al.
Published: (2022-07-01)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
by: Stewart J Tepper, et al.
Published: (2021-07-01)

Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea
by: Byung-Kun Kim, et al.
Published: (2021-05-01)

Migraine awareness, prevalence, triggers, and impact on university students: a cross-sectional study
by: Ayah Rustom, et al.
Published: (2022-10-01)

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab
by: Ciro De Luca, et al.
Published: (2021-10-01)

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01)

Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment
by: Francesca Schiano di Cola, et al.
Published: (2019-07-01)

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
by: Virginia L. Stauffer, et al.
Published: (2020-06-01)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019-04-01)

Fibromyalgia in migraine: a retrospective cohort study
by: Mark Whealy, et al.
Published: (2018-07-01)

Acupuncture Decreases Attack Frequency and Improves Disability in Patients with Migraine Without Aura: A Randomized Controlled Trial
by: Rabia Rukiye Akinci, et al.
Published: (2022-09-01)

Comparison of pupil size in patients of migraine with photophobia versus normal subjects and correlation of the pupil size to severity of headache
by: Ruby Moharana, et al.
Published: (2024-01-01)

Impact of Amitryptiline on Migraine Disability Assessment Score
by: Kuldeep Moras, et al.
Published: (2014-09-01)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
by: Yazan Bader, et al.
Published: (2023-07-01)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
by: Maurice T. Driessen, et al.
Published: (2022-05-01)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2022-06-01)

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
by: Timothy R. Smith, et al.
Published: (2021-11-01)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
by: Michael Ament, et al.
Published: (2021-02-01)

Involvement of the cerebellum in migraine
by: Mengya Wang, et al.
Published: (2022-10-01)

Evaluation of Vitamin D Levels and Response to Therapy of Childhood Migraine
by: Betül Kılıç, et al.
Published: (2019-06-01)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
by: Root S, et al.
Published: (2023-02-01)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023-04-01)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
by: Valentina Favoni, et al.
Published: (2019-03-01)

Ubrogepant to Treat Acute Migraine in Adults
by: Amber N. Edinoff, et al.
Published: (2021-01-01)